top of page
bggrey.png

SCD Medical Challenges & Emulsified Long Chain Polyunsaturated Fatty Acid

3.png

SCD Medial Challenges

Treating Sickle Cell Disease (SCD) poses numerous medical challenges due to its complexity and impact on various body systems. Some of the medical challenges faced when managing SCD include:

  1. Pain Management: Managing acute and chronic pain effectively while avoiding opioid overuse and dependence is a significant challenge.

  2. Preventing Vaso-Occlusive Crises: Reducing the frequency and severity of VOCs is essential to improving the quality of life for individuals with SCD. This often involves concomitant medications.

  3. Complications and Organ Damage: SCD can lead to various complications, including stroke, acute chest syndrome, avascular necrosis, and organ damage. Preventing and managing these complications are critical challenges.

  4. Infection Risk: Individuals with SCD are at an increased risk of infections, particularly from encapsulated bacteria like Streptococcus pneumoniae. Vaccination and antibiotic prophylaxis are essential strategies.

  5. Transfusion Therapy: Managing chronic transfusion therapy in patients with severe SCD can be challenging due to the risk of iron overload and alloimmunization.

  6. Hydroxyurea Adherence/ Poor Compliance: Ensuring patient compliance with hydroxyurea therapy, which can help reduce the frequency of VOCs and other complications, can be difficult.

  7. Psychosocial and Quality of Life Issues: SCD can have a significant impact on the psychosocial well-being and quality of life of patients, including depression, anxiety, and limitations in daily activities.

  8. Limited Treatment Options: While hydroxyurea is a standard treatment for SCD, there is a need for more targeted therapies and curative options, as well as improved access to these treatments.

  9. Transition from Pediatric to Adult Care: Transitioning adolescents with SCD from pediatric to adult care presents challenges in maintaining continuity of care and addressing the changing medical and psychosocial needs of the patient.

  10. Healthcare Disparities: Racial and socioeconomic disparities in healthcare access and quality can impact the management and outcomes of SCD. Addressing these disparities is crucial for improving care.

It’s important to note that ongoing research and advancements in the field of SCD are continually addressing these challenges, with the aim of improving the quality of life and life expectancy for individuals with SCD. However, the complexity of the disease requires a multidisciplinary approach involving hematologists, pain specialists, psychologists, social workers, and other healthcare providers to provide comprehensive care and support for patients with SCD. Consider if Emulsified Long Chain Polyunsaturated Fatty AcidReplacement therapy fits into your patient’s daily routine.

 Emulsified Long Chain Polyunsaturated Fatty Acid (LCPUFA) Replacement

Multiple clinical trials have demonstrated high levels of LCPUFA in the blood can help lower certain pro-inflammatory proteins and decrease oxidative stress within the bloodstream.

  1. Inflammation and oxidative stress are key components to triggering VOCs.

  2. Increased levels of LCPUFA support cell membrane integrity, plasticity and fluidity

  3. Increased levels of LCPUFA reduce hemoglobin mutation preventing oxidation

  4. Reduction in oxidation helps prevent RBC destruction (hemolysis)

  5. Overall inflammation is lowered by reduction in hemolysis.

  6. DHA critically serves to stop the inflammatory cascade (increases in WBC, platelets and adhesion molecules) leading to stickiness, clusters and blockages all causing VOCs.

When the oxidation and chronic inflammation is blocked, the remaining cascade of events (hypoxia/ lack of oxygen, sickling of cells, increased stickiness, clusters, blockages) leading to a vaso-inclusive crisis are greatly reduced.

ALTEMIA is the only Medical Food replacement formulated specifically for sickle cell disease patients utilizing Natural Emulsion Technology™ to deliver reliable increased LCPUFA levels safely and consistently to the bloodstream. There are no equivalents comparable to ALTEMIA’s purity, quality, safety and dosing convenience.

bottom of page